CD40 and autoimmune disease: KPL-404 did not exert any agonistic activity on B cells in vitro and inhibited CD40L-CD40-dependent B cell activation at nanomolar concentrations, providing a basis for further testing of KPL-404 in patients with autoimmune diseases.